2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04788745
(ClinicalTrials.gov)
June 29, 20212/3/2021Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)Targeting Metabolic Flexibility in ALS (MetFlex); Safety and Tolerability of Trimetazidine for the Treatment of ALSAmyotrophic Lateral Sclerosis;Motor Neuron DiseaseDrug: Trimetazidine DihydrochlorideThe University of QueenslandFightMND;UMC Utrecht;King's College London;Julius Clinical, The NetherlandsRecruiting18 Years75 YearsAll36Phase 2Australia;Netherlands;United Kingdom
2EUCTR2020-005018-17-NL
(EUCTR)
14/05/202108/04/2021Safety and tolerability of Trimetazidine in amyotrophic lateral sclerosis (ALS)Targeting metabolic flexibility in ALS (MetFlex); Safety and tolerability of Trimetazidine for the treatment of ALS - MetFlex Patients suffering from amyotrophic lateral sclerosis (ALS);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Vastarel
Product Name: Trimetazidine
Product Code: 201600930
The University of QueenslandNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
36Phase 2Australia;Netherlands